Project Completion Report (Methyl Bromide Demonstration ：工程竣工报告（甲基溴化铵示范

1、Project Completion Report*(Methyl Bromide Demonstration Projects)SECTION 1: PROJECT OVERVIEW1.1COUNTRY: 1.2PROJECT NUMBER (AS PER INVENTORY):PROJECT NUMBER1.3PROJECT TITLE 1.4ADDRESS(ES) OF ENTERPRISE AND PROJECT SITE(S): 1.5DATE OF APPROVAL OF THE PROJECT (AS PER INVENTORY): APPROVEDACTUALOriginal:

2、 1.6DATE OF COMPLETIONLatest Revised: (choose from list) (choose from list) 1.7ALTERNATIVES TESTED:*(choose from list) (choose from list) 1.8ODP PHASE-OUT: (IF APPLICABLE)0.000.001.9TOTAL MLF FUNDING: 0 01.10TOTAL COUNTERPART FUNDING (FOR ELIGIBLE INCREMENTAL COST) 0 01.11TOTAL PROJECT COST: 0 0MLF

3、FUNDING!Zero Divide!Zero Divide1.12COST-EFFECTIVENESS:TOTAL COST!Zero Divide!Zero DivideCOMPLETION REPORT DONE/SEEN BY:AGENCYNAME, SIGNATURE*, DATE1.13IMPLEMENTING AGENCY: 1.14EXECUTING AGENCY/FINANCIAL INTERMEDIARY: 1.15NATIONAL COORDINATING AGENCY/NOU: 1.16PARTNER INSTITUTION * If the actual techn

4、ology used is different from the approved one, indicate procedures followed with regard to informing the Executive Committee and seeking approval in accordance with the guidelines established by Decision 22/69:* Signing the PCR means confirming to have seen it, not necessarily to agree to all statem

5、ents. Differences of opinion may be explained in comments at the end of Section 3.Explanations, if needed: *Indicate whether this report is provisional or final .SECTION 2: CRITERIA AND RATING SCHEME FOR OVERALL ASSESSMENTNot applicable.SECTION 3: DESCRIPTIVE ASSESSMENT OF PROJECT PERFORMANCEThe fol

6、lowing questions are to summarize actual performance as compared to what was approved in the project document.3.1Explain reasons if new alternatives, different from project document, were tested:3.2Describe main post-conversion safety, health and environmental risks (in comparison to baseline condit

7、ions) and measures taken to cope with such risks for the alternatives tested:3.3Report on implementation of Executive Committee approval conditions (in cases of approval with specified conditions):3.4Comments on differences between approved and actual figures for capital, operational and contingency

8、 costs and actions taken to cope with cost overruns:3.5Report on reasons for changes in counterpart funding for eligible incremental costs:3.6Describe and categorize any major (technical, financial, process or other) problems encountered in project implementation, causes of delays and actions taken

9、to overcome them:CategoriesCauses of DelayActions taken to Overcome Delay(s)a) due to Implementing Agency delays b) due to enterprise delays c) due to equipment / chemical supplier delays d) due to Governmental delays e) due to external (regional/global) factors f) due to delays in funding following

10、 project approval 3.7Lessons learned for future action:3.8Comments of the partner institution:3.9Governments / NOUs comments:3.10Comments of the Executing Agency/Financial Intermediary:3.11Comments of the Implementing Agency:Comment PN1: This amount is calculated automatically from the disbursements

11、 below.SECTION 4: ODS PHASE-OUTNot applicable.SECTION 5: BUDGET AND EXPENDITURESIn case this PCR is still provisional (as indicated in Section 1), this may serve as a status report on project expenditures at the time of preparing the Project Completion Report with the understanding that a final fina

12、ncial completion report will be prepared as an update once the accounts of the project are closed.5.1Total budget and expenditure on incremental cost:The following relationships must be applied in table 5.1, and are automatically calculated on the electronic form:Total Cost / Funding = Incremental C

13、apital Costs + Contingency + IOCTotal Counterpart Funding = Total Approved Costs Total Approved MLF GrantActual Costs = Grant Funds + Counterpart FundsIOC Grant Funding Disbursed = First disbursement amount + Second disbursement amount + Third disbursement amountTotal MLF Grant Not Utilized = Total

14、MLF Grant Actual Total Grant Funding DisbursedProject BudgetApproved CostsActual Total Funding DisbursedActual CostsGrant FundsCounterpart FundsIncremental Capital Costs000 0Contingency00IOC*0 00 0Total Costs / Funding 0 0 0 0Total MLF Grant*0Total Counterpart Funding* 0Total MLF Grant Not Utilized

15、0The total IOC disbursement in this table is calculated automatically from the breakdown given here.Indicate date(s) and amount(s) of IOC disbursement(s) by Implementing Agency:First amount: 0 and date: ; second amount: 0 and date: ; third amount: 0 and date: .Explanations, if needed: *If IOC funds

16、were used to finance incremental capital costs, in accordance with ExCom Decision 20/6, the amount should be specified in Section 3.6 above.* Including adjustments, if any were approved. Differences between total approved costs and total MLF grant may be due to non-Art. 5 country ownership and/or ex

17、ports to Art. 2 countries (see Sections 1.13 and 1.14 above). Other reasons are costs above the threshold level, a reduction of funding for technological up-grades, incremental operating savings or capacity increase.* Counterpart funding for eligible incremental costs resulting from situations as de

18、scribed in footnote* above.5.2Detailed list of equipment and services:Project BudgetApproved CostsActual FundingActual CostsGrant FundsCounterpart FundsIncremental Capital Costs*SubtotalContingency*Explanations, if needed: *List of equipment capital cost, including cost for international consultants

19、, by item as approved in the project document (additional equipment should be so indicated). If the company insists on purchasing equipment for more than the limits established through international bidding, please provide detailed explanation in Section 3.6 above.*Specify use of contingency by item

20、 under explanations, if it does not become clear enough by comparing approved and actual cost by item.5.3Counterpart funding of additional items not included in the project document (based on information provided by the company/beneficiary):ITEMSACTUAL EXPENDITURES1.2.3.TOTALExplanations, if needed: SECTION 6: IMPLEMENTATION EFFICIENCYProject Milestones*Planned DatesPlanned Duration in Months*Actual DateActual Duration in Months*Delay in MonthsExCom approval dateStart-up of project activities at